发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report. 晚期胃癌超高龄患者对卡多尼单抗一线治疗的良好反应：病例报告。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-11 DOI: 10.1080/1750743x.2024.2394405
Jia Lun,Guikai Ma,Xuan Wang,Qian Wang
{"title":"Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report.","authors":"Jia Lun,Guikai Ma,Xuan Wang,Qian Wang","doi":"10.1080/1750743x.2024.2394405","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2394405","url":null,"abstract":"Gastric cancer remains a considerable global health burden, with limited treatment options available for advanced cases, especially for superaged patients. Cadonilimab, a first-in-class bi-specific antibody (BsAb), offer a promising immunotherapy approach by targeting PD-1/CTLA-4 simultaneously. Herein, we present a case report of an 85-year-old patient with HER2-negative advanced gastric cancer who received first-line treatment with cadonilimab combined with chemotherapy, but cadonilimab was discontinued due to the observation of immune-related pneumonitis during treatment. Despite these changes, the patient still exhibited a stable disease condition for a year until now. This case report highlights the potential of cadonilimab in the treatment of superaged patients with advanced gastric cancer, while the efficacy and safety of it need to be further evaluated.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report. PD-1 抗体诱导的复发性鼻咽癌伴胆囊炎的成功置换：病例报告。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-09-04 DOI: 10.1080/1750743X.2024.2382670
Zheqing Liu, Xiaojing Du, Meiling Deng, Yuanyuan Chen, Shaoxiong Wu
{"title":"Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report.","authors":"Zheqing Liu, Xiaojing Du, Meiling Deng, Yuanyuan Chen, Shaoxiong Wu","doi":"10.1080/1750743X.2024.2382670","DOIUrl":"https://doi.org/10.1080/1750743X.2024.2382670","url":null,"abstract":"<p><p>The occurrence of immune-related cholecystitis and the subsequent immunotherapy re-challenge has been rarely reported. A patient diagnosed with recurrent nasopharyngeal carcinoma, developed immune-related cholecystitis after the sixth and eighth cycles of camrelizumab respectively. The patient's symptoms and laboratory test results showed improvement after conservative treatment. Then we chose zimberelimab, a fully humanized PD-1 antibody, as a replacement for camrelizumab in maintenance therapy and successfully completed 37 cycles of zimberelimab (240 mg every 2 weeks per cycle). Surprisingly, the patient experienced no immune-related adverse event and remained in complete remission with a progression-free survival of 28.8 months. The use of Zimberelimab as rechallenge immunotherapy may be an optional choice after managing immune-related cholecystitis induced by other PD-1 antibodies.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineered T cells for Colorectal Cancer. 治疗结直肠癌的工程 T 细胞。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-09-04 DOI: 10.1080/1750743X.2024.2391733
Nurul Ainaa Adilah Rus Bakarurraini, Ammar Akram Kamarudin, Rahman Jamal, Nadiah Abu
{"title":"Engineered T cells for Colorectal Cancer.","authors":"Nurul Ainaa Adilah Rus Bakarurraini, Ammar Akram Kamarudin, Rahman Jamal, Nadiah Abu","doi":"10.1080/1750743X.2024.2391733","DOIUrl":"https://doi.org/10.1080/1750743X.2024.2391733","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a major contributor to global cancer incidence and mortality. Conventional treatments have limitations; hence, innovative approaches are imperative. Recent advancements in cancer research have led to the development of personalized targeted therapies and immunotherapies. Immunotherapy, in particular, T cell-based therapies, exhibited to be promising in enhancing cancer treatment outcomes. This review focuses on the landscape of engineered T cells as a potential option for the treatment of CRC. It highlights the approaches, challenges and current advancements in this field. As the understanding of molecular mechanisms increases, engineered T cells hold great potential in revolutionizing cancer treatment. To fully explore their safety efficacy in improving patient outcomes, further research and clinical trials are necessary.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy and transarterial embolization in patients with metastatic melanoma: a retrospective cohort study. 转移性黑色素瘤患者的免疫疗法和经动脉栓塞治疗：一项回顾性队列研究。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-09-03 DOI: 10.1080/1750743X.2024.2382665
Leila Haghani, Chenyang Zhan, Hooman Yarmohammadi, Etay Ziv, Vlasios S Sotirchos, Debkumar Sarkar, Alexander N Shoushtari, Joseph P Erinjeri
{"title":"Immunotherapy and transarterial embolization in patients with metastatic melanoma: a retrospective cohort study.","authors":"Leila Haghani, Chenyang Zhan, Hooman Yarmohammadi, Etay Ziv, Vlasios S Sotirchos, Debkumar Sarkar, Alexander N Shoushtari, Joseph P Erinjeri","doi":"10.1080/1750743X.2024.2382665","DOIUrl":"https://doi.org/10.1080/1750743X.2024.2382665","url":null,"abstract":"<p><p><b>Aim:</b> To investigate how the sequence of checkpoint immunotherapy (CPI) and transarterial embolization (TAE) affects overall survival (OS) of patients with metastatic melanoma.<b>Materials & methods:</b> This retrospective cohort study included 65 patients with metastatic melanoma who underwent both TAE and CPI between September 2011 and January 2022.<b>Results:</b> Significantly higher OS was seen in patients who received CPI before and after embolization (22 months, 95% CI 14-NR, <i>p</i> < 0.001) compared with only before embolization (4.5 months 95% CI, 14-NR). ≤3 hepatic metastasis (<i>p</i> < 0.01), more TAE procedures (<i>p</i> < 0.001) and CPI sequence (before and after embolization) (<i>p</i> < 0.001) were independent predictors of survival.<b>Conclusion:</b> Metastatic melanoma patients who underwent TAE have longer survival when CPI was sequenced both before and after embolization.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report. 双检查点抑制剂治疗后的恶性免疫相关性结肠炎：病例报告。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-08-19 DOI: 10.1080/1750743X.2024.2386234
Robert Lukin, Aaron Ciner
{"title":"Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report.","authors":"Robert Lukin, Aaron Ciner","doi":"10.1080/1750743X.2024.2386234","DOIUrl":"https://doi.org/10.1080/1750743X.2024.2386234","url":null,"abstract":"<p><p><b>Aim:</b> Immune-related (IR) colitis is a potentially life-threatening complication of checkpoint inhibitors. Its presentation often includes diarrhea, abdominal pain and rectal bleeding and the median time to onset is 6-10 weeks post initiation of immunotherapy. <b>Case study:</b> We report an unusual case of fulminant IR-colitis beginning 3 days after the first dose of dual checkpoint blockade. IR-colitis was refractory to high-dose corticosteroids and was further complicated by sigmoid diverticulum perforation. <b>Conclusion:</b> Early-onset IR-colitis can occur, particularly in the context of combined anti-PD1 and anti-CTLA4 blockade, and clinicians should maintain a high-index of suspicion even when timing of symptom onset is atypical. Further research is needed to elucidate risk factors for early-onset IR-colitis.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. 接受 nivolumab 治疗的转移性肾细胞癌患者既往 TKI 类型的预后价值。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-08-19 DOI: 10.1080/1750743X.2024.2385881
Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti
{"title":"Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.","authors":"Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti","doi":"10.1080/1750743X.2024.2385881","DOIUrl":"https://doi.org/10.1080/1750743X.2024.2385881","url":null,"abstract":"<p><p><b>Aim:</b> To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.<b>Materials and methods:</b> A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.<b>Results:</b> There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.<b>Conclusion:</b> There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of nemolizumab in the treatment of atopic dermatitis for the adult population. 奈莫利单抗在成人特应性皮炎治疗中的作用。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-08-09 DOI: 10.1080/1750743X.2024.2383554
Stuti Prajapati, Joseph P Flemming, Danyaal Khan, Haowei Han, Brian How, Suzanne Sirota Rozenberg, Steven R Feldman
{"title":"The role of nemolizumab in the treatment of atopic dermatitis for the adult population.","authors":"Stuti Prajapati, Joseph P Flemming, Danyaal Khan, Haowei Han, Brian How, Suzanne Sirota Rozenberg, Steven R Feldman","doi":"10.1080/1750743X.2024.2383554","DOIUrl":"https://doi.org/10.1080/1750743X.2024.2383554","url":null,"abstract":"<p><p>Atopic dermatitis (AD) often requires long-term treatment that may be associated with adverse effects. This review aims to characterize nemolizumab as a treatment for AD in adults. A literature search was performed to assess nemolizumab's role in moderate-to-severe AD in adults. Currently, clinical trials are being conducted to evaluate the clinical efficacy, safety profile and optimal dosing of nemolizumab for adults with moderate-to-severe AD. The most common adverse effects include nasopharyngitis, AD exacerbation and increased blood creatinine phosphokinase. Recent data from clinical trials suggest nemolizumab may be an acceptable treatment in adults with moderate-to-severe AD.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The development of anti-PD-1 antibody-induced spinal cord injury in bone marrow transplant C57BL/6 Rag1-/- mouse model. 骨髓移植 C57BL/6 Rag1-/- 小鼠模型中抗 PD-1 抗体诱导的脊髓损伤的发展。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-08-08 DOI: 10.1080/1750743X.2024.2383557
Huachun Chen, Zhouxiao Lu, Xiaowei Ni, Hui Zhang, Guiyuan Chen, Xiaoyu Wu, Mingxing Ding
{"title":"The development of anti-PD-1 antibody-induced spinal cord injury in bone marrow transplant C57BL/6 <i>Rag1<sup>-/-</sup></i> mouse model.","authors":"Huachun Chen, Zhouxiao Lu, Xiaowei Ni, Hui Zhang, Guiyuan Chen, Xiaoyu Wu, Mingxing Ding","doi":"10.1080/1750743X.2024.2383557","DOIUrl":"https://doi.org/10.1080/1750743X.2024.2383557","url":null,"abstract":"<p><p><b>Aims:</b> This paper was to scrutinize the toxicity mechanism of anti-programmed death 1 (anti-PD-1) therapy-caused spinal cord injury (SCI). <b>Methods:</b> Bone marrow transplant <i>Rag1<sup>-/-</sup></i> mice were used to establish SCI model. <b>Results:</b> Anti-PD-1 results in SCI via CD8<sup>+</sup> T-cells activation, while excessive activation of CD8<sup>+</sup> T-cells further aggravated SCI. Both anti-PD-1 and the activation of CD8<sup>+</sup> T-cells induced the expression of apoptosis-related perforin, GrB and FasL, but suppressed PI-9 level. The opposite results were observed in the effects of neuroserpin on these factors. CD8<sup>+</sup> T-cells activation induced neurotoxicity via upregulation perforin, GrB and FasL and inhibiting PI-9. Additionally, neuroserpin suppressed CD8<sup>+</sup> T-cells activation via perforin/GrB/PI-9/FasL pathways. <b>Conclusion:</b> These results may provide theoretical foundation for the clinical treatment of SCI caused by anti-PD-1.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study. Meet-URO 15 研究中基于红细胞的转移性 RCC 患者预后评分。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-08-06 DOI: 10.1080/1750743X.2024.2382666
Shobana Anpalakhan, Giuseppe Luigi Banna, Sara Elena Rebuzzi, Giuseppe Fornarini, Marco Maruzzo, Paolo Andrea Zucali, Fabio Catalano, Ludovica Antonj, Marianna Tudini, Lucia Fratino, Andrea Malgeri, Pasquale Rescigno, Alessio Signori, Alessandro Acunzo, Enrico Maria Silini, Giulia Mazzaschi, Sebastiano Buti
{"title":"A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study.","authors":"Shobana Anpalakhan, Giuseppe Luigi Banna, Sara Elena Rebuzzi, Giuseppe Fornarini, Marco Maruzzo, Paolo Andrea Zucali, Fabio Catalano, Ludovica Antonj, Marianna Tudini, Lucia Fratino, Andrea Malgeri, Pasquale Rescigno, Alessio Signori, Alessandro Acunzo, Enrico Maria Silini, Giulia Mazzaschi, Sebastiano Buti","doi":"10.1080/1750743X.2024.2382666","DOIUrl":"https://doi.org/10.1080/1750743X.2024.2382666","url":null,"abstract":"<p><p><b>Aims:</b> Anemia, mean corpuscular volume and red cell distribution width may have some effects on survival outcomes of metastatic renal cell carcinoma (mRCC) patients and are incorporated in a red blood cell (RBC)-based score. Its validity in prognostication of mRCC patients treated with second-line nivolumab was assessed. <b>Patients and methods:</b> Retrospective analysis using Meet-URO-15 cohort of mRCC patients receiving nivolumab in the second-line setting or beyond. Outcomes were overall survival (OS) and progression-free survival (PFS). <b>Results:</b> A total of 390 patients were included. Significant differences in OS and PFS between RBC-based score groups, with group 1 (2 or 3 of the RBC-related prognostic factors) having longer OS (median 29.5 months, 95% CI: 23.1-35.9, versus 11.5 months, 95% CI: 8.5-22.6; <i>p</i> < 0.001) and PFS (7.5 months, 95% CI: 5.5-10.2, versus 4.2 months, 95% CI: 3.3-5.9; <i>p</i> = 0.040) than those in group 0 (0 or 1 RBC-related prognostic factors). Belonging to group 1 independently predicted OS (hazard ratio: 0.65, 95% CI: 0.50-0.85; <i>p</i> = 0.002) but not PFS (hazard ratio: 0.89, 95% CI: 0.70-1.14, <i>p</i> = 0.370) or disease response (OR 0.68, 95% CI: 0.41-1.10; <i>p</i> = 0.118) at multivariable analysis. <b>Conclusion:</b> RBC-based group scores independently predicted OS in mRCC patients treated with nivolumab.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selection of allergen extract for immunotherapy in polysensitized allergic rhinitis patients 为多过敏性鼻炎患者的免疫疗法选择过敏原提取物
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-06-03 DOI: 10.1080/1750743x.2024.2342225
Elizabeth García, J. Ardila, Nardey Crespo, Edgardo Chapman, Jaime Ocampo, Margarita Olivares, Ana-Milena Acevedo, Natalia Aguirre, Steven Abreu, Ana Calle, Ruth Ramírez, Jorge Sánchez
{"title":"Selection of allergen extract for immunotherapy in polysensitized allergic rhinitis patients","authors":"Elizabeth García, J. Ardila, Nardey Crespo, Edgardo Chapman, Jaime Ocampo, Margarita Olivares, Ana-Milena Acevedo, Natalia Aguirre, Steven Abreu, Ana Calle, Ruth Ramírez, Jorge Sánchez","doi":"10.1080/1750743x.2024.2342225","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2342225","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141273030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信